Clinical trial
CONNECTION PLUS: An Open-Label Extension of the CONNECTION Protocol (DIM14) Evaluating Oral Dimebon in Patients with Alzheimer�s Disease
To evaluate the long-term safety and tolerability of Dimebon in Alzheimer�s Disease (AD) patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION protocol (DIM14).
| Category | Value |
|---|---|
| Study start date | 2009-03-31 |